PMID- 29632734
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 2162-4011 (Print)
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Linking)
VI  - 7
IP  - 4
DP  - 2018
TI  - Bladder cancer-associated cancer-testis antigen-derived long peptides 
      encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes 
      induced CD4(+) T cells expressing converged T-cell receptor genes in vitro.
PG  - e1415687
LID - 10.1080/2162402X.2017.1415687 [doi]
LID - e1415687
AB  - DEP domain containing 1 (DEPDC1) and M-phase phosphoprotein 1 (MPHOSPH1) are 
      human cancer testis antigens that are frequently overexpressed in urinary bladder 
      cancer. In a phase I/II clinical trial, a DEPDC1- and MPHOSPH1-derived short 
      peptide vaccine demonstrated promising efficacy in preventing bladder cancer 
      recurrence. Here, we aimed to identify long peptides (LPs) derived from DEPDC1 
      and MPHOSPH1 that induced both T-helper (Th) cells and tumor-reactive cytotoxic T 
      lymphocytes (CTLs). Stimulation of peripheral blood mononuclear cells (PBMCs) 
      from healthy donors with the synthetic DEPDC1- and MPHOSPH1-LPs predicted to bind 
      to promiscuous human leukocyte antigen (HLA) class II molecules by a computer 
      algorithm induced specific CD4(+) T cells as revealed by interferon-gamma 
      enzyme-linked immunospot assays. Three of six LPs encompassed HLA-A2- or 
      -A24-restricted CTL epitopes or both, and all six LPs stimulated DEPDC1- or 
      MPHOSPH1-specific Th cells restricted by promiscuous and frequently observed HLA 
      class II molecules in the Japanese population. Some LPs are naturally processed 
      from the proteins in DCs, and the capacity of these LPs to cross-prime CTLs was 
      confirmed in vivo using HLA-A2 or -A24 transgenic mice. The LP-specific and HLA 
      class II-restricted T-cell responses were also observed in PBMCs from patients 
      with bladder cancer. Repeated stimulation of PBMCs with DEPDC1-LPs and 
      MPHOSPH1-LPs yielded clonal Th cells expressing specific T-cell receptor (TCR)-alpha 
      and beta genes. These DEPDC1- or MPHOSPH1-derived LPs may have applications in 
      immunotherapy in patients with bladder cancer, and the TCR genes identified may 
      be useful for monitoring of Th cells specific to LPs in vivo.
FAU - Tsuruta, Miki
AU  - Tsuruta M
AD  - Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto 
      University, Honjo, Chuo-ku, Kumamoto, Japan.
AD  - Department of Oral and Maxillofacial Surgery, Graduate School of Medical 
      Sciences, Kumamoto University, Honjo, Chuo-ku, Kumamoto, Japan.
FAU - Ueda, Shohei
AU  - Ueda S
AD  - Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto 
      University, Honjo, Chuo-ku, Kumamoto, Japan.
AD  - Department of Urology, Graduate School of Medical Sciences, Kyushu University, 
      Maidashi, Higashi-ku, Fukuoka, Japan.
FAU - Yew, Poh Yin
AU  - Yew PY
AD  - Tumor Immunoanalysis Department, OncoTherapy Science, Inc., Sakado, Takatsu-ku, 
      Kawasaki, Kanagawa, Japan.
FAU - Fukuda, Isao
AU  - Fukuda I
AD  - Tumor Immunoanalysis Department, OncoTherapy Science, Inc., Sakado, Takatsu-ku, 
      Kawasaki, Kanagawa, Japan.
FAU - Yoshimura, Sachiko
AU  - Yoshimura S
AD  - Tumor Immunoanalysis Department, OncoTherapy Science, Inc., Sakado, Takatsu-ku, 
      Kawasaki, Kanagawa, Japan.
FAU - Kishi, Hiroyuki
AU  - Kishi H
AD  - Department of Immunology, Graduate School of Medicine and Pharmaceutical Sciences 
      (Medicine), University of Toyama, Sugitani, Toyama, Toyama, Japan.
FAU - Hamana, Hiroshi
AU  - Hamana H
AD  - Department of Innovative Cancer Immunotherapy, Graduate School of Medicine and 
      Pharmaceutical Sciences, University of Toyama, Sugitani, Toyama, Toyama, Japan.
FAU - Hirayama, Masatoshi
AU  - Hirayama M
AD  - Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto 
      University, Honjo, Chuo-ku, Kumamoto, Japan.
AD  - Department of Oral and Maxillofacial Surgery, Graduate School of Medical 
      Sciences, Kumamoto University, Honjo, Chuo-ku, Kumamoto, Japan.
FAU - Yatsuda, Junji
AU  - Yatsuda J
AD  - Department of Urology, Graduate School of Medical Sciences, Kumamoto University, 
      Honjo, Chuo-ku, Kumamoto, Japan.
FAU - Irie, Atsushi
AU  - Irie A
AD  - Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto 
      University, Honjo, Chuo-ku, Kumamoto, Japan.
FAU - Senju, Satoru
AU  - Senju S
AD  - Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto 
      University, Honjo, Chuo-ku, Kumamoto, Japan.
FAU - Yuba, Eiji
AU  - Yuba E
AD  - Department of Applied Chemistry, Graduate School of Engineering, Osaka Prefecture 
      University, Gakuen-cho, Naka-ku, Sakai, Osaka, Japan.
FAU - Kamba, Tomomi
AU  - Kamba T
AD  - Department of Urology, Graduate School of Medical Sciences, Kumamoto University, 
      Honjo, Chuo-ku, Kumamoto, Japan.
FAU - Eto, Masatoshi
AU  - Eto M
AD  - Department of Urology, Graduate School of Medical Sciences, Kyushu University, 
      Maidashi, Higashi-ku, Fukuoka, Japan.
AD  - Department of Urology, Graduate School of Medical Sciences, Kumamoto University, 
      Honjo, Chuo-ku, Kumamoto, Japan.
FAU - Nakayama, Hideki
AU  - Nakayama H
AD  - Department of Oral and Maxillofacial Surgery, Graduate School of Medical 
      Sciences, Kumamoto University, Honjo, Chuo-ku, Kumamoto, Japan.
FAU - Nishimura, Yasuharu
AU  - Nishimura Y
AD  - Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto 
      University, Honjo, Chuo-ku, Kumamoto, Japan.
AD  - Nishimura Project Laboratory, Center for Resource Development and Analysis, 
      Kumamoto University, Honjo, Chuo-ku, Kumamoto, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180105
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
PMC - PMC5889196
OTO - NOTNLM
OT  - DEP domain containing 1
OT  - M-phase phosphoprotein 1
OT  - T-cell receptor
OT  - bladder cancer
OT  - cancer immunotherapy
OT  - cancer-testis antigen
OT  - cross presentation
OT  - helper T-cell epitope
OT  - tumor immunity
EDAT- 2018/04/11 06:00
MHDA- 2018/04/11 06:01
PMCR- 2019/01/05
CRDT- 2018/04/11 06:00
PHST- 2017/10/11 00:00 [received]
PHST- 2017/12/02 00:00 [revised]
PHST- 2017/12/04 00:00 [accepted]
PHST- 2018/04/11 06:00 [entrez]
PHST- 2018/04/11 06:00 [pubmed]
PHST- 2018/04/11 06:01 [medline]
PHST- 2019/01/05 00:00 [pmc-release]
AID - 1415687 [pii]
AID - 10.1080/2162402X.2017.1415687 [doi]
PST - epublish
SO  - Oncoimmunology. 2018 Jan 5;7(4):e1415687. doi: 10.1080/2162402X.2017.1415687. 
      eCollection 2018.